Intas Rumored As Another Suitor For Biogen’s Biosimilars Business
Reports Of Interest From Accord Parent Company Follow Earlier Samsung Bioepis Rumor
Reports have named Intas as another possible buyer for Biogen’s biosimilars business, following earlier rumors that Samsung Bioepis could be interested in a deal. Generics Bulletin spoke to both Intas and Biogen for their reaction.
You may also be interested in...
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
As Biogen provided an update on a potential sale of its biosimilars business – with the firm “engaged with multiple interested parties” – it also revealed Q2 sales and offered insights into off-patent competition to its Tysabri and Tecfidera brands.
Intas has announced that its Accord Healthcare unit has filed in Europe the DMB-3115 biosimilar ustekinumab candidate licensed from Japan’s Meiji Seika Pharma and Korea’s Dong-A.